Sanofi Pasteur Inc.

Laurence Quemeneur

Jacqueline McCluskey

Bachra Rokbi

Jeremy Yethon

Robert Charlebois

Raffaella Iantomasi

Marie-Pierre Kazek-duret

Michael Leach

John Shiver

Nadège Arnaud-barbe

Vinod Balhara

The present disclosure relates to an immunogenic composition comprising a combination of meningococcal antigens which comprises at least one factor H binding protein (fHBP) A protein, at least one fHBP B protein, at least oneadhesin A (NadA) protein, and at least one detergent-extracted Outer Membrane Vesicle (dOMV). The meningococcal antigens may be from aserogroup B. The combination of antigens provided a broad coverage of bacteria strains. Further, the present disclosure relates to the use of the immunogenic composition in methods for eliciting an immune response.

Meningococcal B recombinant vaccine

Provided herein are compositions and methods for eliciting an immune response against. The compositions and methods relate topolypeptides and fragments and variants thereof and the corresponding polynucleotides which are useful in the diagnosis, prevention and therapy ofinfections (e.g. periodontitis). Antibodies against the polypeptides and compositions and methods including these antibodies are also disclosed. The disclosure also describes methods for the detection, prevention and treatment ofinfection (e.g. periodontitis).

Porphyromonas gingivalis polypeptides

Growing community of inventors

Marcy l'Etoile, France

Laurence Quemeneur